MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- MERCK LIMITED (pharmaceuticals)
- MERCK LIMITED Financial Data
Merck Ltd Fact Sheet 
(EMER)
Here is the latest financial fact sheet of Merck Ltd. For more details, see the Merck Ltd quarterly results and Merck Ltd share price and chart. For a sector overview, read our pharmaceuticals sector report.
MERCK Price History
| % ch | % | 2.7 |
| No. of shares | m | 16.60 |
| % ch week | % | 20.3 |
| % ch 1-mth | % | 17.9 |
| % ch 12-mth | % | 115.9 |
| 52 week H/L | Rs | 4,389.0/1,845.0 |
MERCK Financials
| No. of Mths Year Ending |
12 Dec-13 |
12 Dec-14 |
12 Dec-15 |
12 Dec-16 |
12 Dec-17 |
5-Yr Chart Click to enlarge
|
|---|
| MERCK EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 689 | 919 | 1,004 | 1,060 | 1,358 | |
| Low | Rs | 523 | 536 | 716 | 623 | 933 | |
| Sales per share (Unadj.) | Rs | 480.6 | 522.6 | 566.0 | 597.9 | 665.0 | |
| Earnings per share (Unadj.) | Rs | 33.7 | 26.0 | 32.3 | 45.7 | 56.6 | |
| Diluted earnings per share | Rs | 33.7 | 26.0 | 32.3 | 45.7 | 56.6 | |
| Cash flow per share (Unadj.) | Rs | 39.7 | 33.7 | 46.4 | 60.7 | 72.5 | |
| Dividends per share (Unadj.) | Rs | 8.50 | 6.00 | 7.50 | 11.00 | 15.00 | |
| Adj. dividends per share | Rs | 8.50 | 6.00 | 7.50 | 11.00 | 15.00 | |
| Dividend yield (eoy) | % | 1.4 | 0.8 | 0.9 | 1.3 | 1.3 | |
| Book value per share (Unadj.) | Rs | 315.1 | 333.9 | 356.4 | 388.8 | 441.7 | |
| Adj. book value per share | Rs | 315.1 | 333.9 | 356.4 | 388.8 | 441.7 | |
| Shares outstanding (eoy) | m | 16.60 | 16.60 | 16.60 | 16.60 | 16.60 | |
| Bonus/Rights/Conversions | - | - | - | - | - | ||
| Price / Sales ratio | x | 1.3 | 1.4 | 1.5 | 1.4 | 1.7 | |
| Avg P/E ratio | x | 18.0 | 27.9 | 26.7 | 18.4 | 20.2 | |
| P/CF ratio (eoy) | x | 15.2 | 21.6 | 18.5 | 13.9 | 15.8 | |
| Price / Book Value ratio | x | 1.9 | 2.2 | 2.4 | 2.2 | 2.6 | |
| Dividend payout | % | 25.3 | 23.0 | 23.2 | 24.1 | 26.5 | |
| Avg Mkt Cap | Rs m | 10,056 | 12,075 | 14,276 | 13,969 | 19,011 | |
| No. of employees | `000 | 1.5 | 1.5 | 1.6 | 1.6 | 1.5 | |
| Total wages/salary | Rs m | 1,010 | 1,136 | 1,234 | 1,542 | 1,696 | |
| Avg. sales/employee | Rs Th | 5,332.8 | 5,726.0 | 6,045.7 | 6,270.1 | 7,150.0 | |
| Avg. wages/employee | Rs Th | 674.9 | 749.6 | 794.0 | 974.3 | 1,098.7 | |
| Avg. net profit/employee | Rs Th | 373.5 | 285.3 | 344.7 | 479.4 | 608.2 | |
| MERCK INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 7,978 | 8,675 | 9,395 | 9,926 | 11,040 | |
| Other income | Rs m | 215 | 203 | 233 | 244 | 240 | |
| Total revenues | Rs m | 8,192 | 8,878 | 9,628 | 10,170 | 11,279 | |
| Gross profit | Rs m | 769 | 589 | 834 | 1,106 | 1,376 | |
| Depreciation | Rs m | 101 | 127 | 234 | 248 | 264 | |
| Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Profit before tax | Rs m | 883 | 666 | 833 | 1,102 | 1,352 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 170 | |
| Tax | Rs m | 324 | 233 | 298 | 343 | 583 | |
| Profit after tax | Rs m | 559 | 432 | 536 | 759 | 939 | |
| Gross profit margin | % | 9.6 | 6.8 | 8.9 | 11.1 | 12.5 | |
| Effective tax rate | % | 36.7 | 35.1 | 35.7 | 31.1 | 43.1 | |
| Net profit margin | % | 7.0 | 5.0 | 5.7 | 7.6 | 8.5 | |
| MERCK BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 4,777 | 4,986 | 5,643 | 6,361 | 7,523 | |
| Current liabilities | Rs m | 1,120 | 1,352 | 1,503 | 1,864 | 2,253 | |
| Net working cap to sales | % | 45.8 | 41.9 | 44.1 | 45.3 | 47.7 | |
| Current ratio | x | 4.3 | 3.7 | 3.8 | 3.4 | 3.3 | |
| Inventory Days | Days | 69 | 75 | 64 | 60 | 52 | |
| Debtors Days | Days | 38 | 44 | 47 | 39 | 41 | |
| Net fixed assets | Rs m | 941 | 1,373 | 1,387 | 1,406 | 1,240 | |
| Share capital | Rs m | 166 | 166 | 166 | 166 | 166 | |
| "Free" reserves | Rs m | 5,062 | 5,374 | 5,844 | 6,472 | 7,167 | |
| Net worth | Rs m | 5,230 | 5,543 | 5,916 | 6,455 | 7,333 | |
| Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Total assets | Rs m | 6,483 | 7,082 | 7,784 | 8,792 | 9,912 | |
| Interest coverage | x | NM | NM | NM | NM | NM | |
| Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
| Sales to assets ratio | x | 1.2 | 1.2 | 1.2 | 1.1 | 1.1 | |
| Return on assets | % | 8.6 | 6.1 | 6.9 | 8.6 | 9.5 | |
| Return on equity | % | 10.7 | 7.8 | 9.1 | 11.8 | 12.8 | |
| Return on capital | % | 16.9 | 12.0 | 14.1 | 17.1 | 20.8 | |
| Exports to sales | % | 8.9 | 7.8 | 8.5 | 8.8 | 0 | |
| Imports to sales | % | 23.7 | 22.8 | 21.6 | 22.3 | 0 | |
| Exports (fob) | Rs m | 708 | 677 | 802 | 869 | 0 | |
| Imports (cif) | Rs m | 1,888 | 1,981 | 2,026 | 2,209 | 0 | |
| Fx inflow | Rs m | 746 | 824 | 874 | 959 | 1,015 | |
| Fx outflow | Rs m | 2,281 | 2,311 | 2,356 | 2,612 | 3,043 | |
| Net fx | Rs m | -1,535 | -1,487 | -1,483 | -1,653 | -2,028 | |
| MERCK CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 5 | 50 | 835 | 1,070 | 537 | |
| From Investments | Rs m | 70 | 106 | -678 | -750 | -476 | |
| From Financial Activity | Rs m | -48 | -166 | -119 | -150 | -220 | |
| Net Cashflow | Rs m | 27 | -11 | 37 | 171 | -160 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: S. N. Talwar | COMP SEC: Vikas R. Gupta | YEAR OF INC: 1967 | BSE CODE: 500126 | FV (Rs): 10 | DIV YIELD (%): 0.3 |
More Pharmaceuticals Company Fact Sheets: ALKEM LABORATORIES AJANTA PHARMA STRIDES PHARMA SCIENCE CIPLA WYETH LTD
Compare MERCK With: ALKEM LABORATORIES AJANTA PHARMA STRIDES PHARMA SCIENCE CIPLA WYETH LTD
Compare MERCK With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Surges Over 1100 Points; SBI and Yes Bank Top Gainers(12:30 pm)
Share markets in India are presently trading on a positive note as investors cheered after exit poll results predicted the return of the BJP-led National Democratic Alliance (NDA) to power.
Views on news
MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)
May 13, 2019 | Updated on May 13, 2019For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.
MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)
Mar 5, 2019 | Updated on Mar 5, 2019For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)
May 7, 2019The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...
3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)
May 10, 2019The one critical element that has made Amazon a force to reckon with...
A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)
May 9, 2019A filtered, neat list of high-dividend stocks with all this dirty work already done for you.
My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
May 16, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
A 10-Bagger in Just 6 Years! The Rebirth of India Will Create More Big Winners Like This(The 5 Minute Wrapup)
May 7, 2019How a niche tech startup battled all odds to eventually become a 10 bagger.
More|
| |
TRACK MERCK
- Track your investment in MERCK with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON MERCK
MERCK - MYLAN COMPARISON
COMPARE MERCK WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.